.Glutamate is the predominant excitatory neurotransmitter in the mammalian central nervous system. Glutamate is normally cleared from the synaptic cleft by high-affinity, sodium-dependent glutamate transporters located in both neurons and glia. Glutamate transport malfunction can lead to the accumulation of excessive glutamate in the synapse, with subsequent neurotoxicity. EAAT2 is an astroglial glutamate transporter and is the predominant glutamate transporter. A loss of this protein has been found in the affected areas of Alzheimer's disease (AD) as well as in amyotrophic lateral sclerosis (ALS). Antisense knockdown studies as well as EAAT2 null mice have demonstrated that loss of EAAT2 protein can lead to excitotoxic neuronal degeneration. What could account for the selective loss of EAAT2 protein in these neurodegenerative diseases? The investigator's recent studies in ALS have demonstrated that the loss of EAAT2 is due to aberrant mRNAs, possibly as a consequence of abnormal splicing. In this study it is proposed to test the possibility that the aberrant mRNAs could account for the loss of EAAT2 in AD. Preliminary results demonstrate that aberrant EAAT2 mRNAs are present in AD specimens. The investigator will determine the abundance of the aberrant EAAT2 mRNA species and evaluate the prevalence of the aberrant EAAT2 mRNAs in AD patients and whether they are correlated with loss of EAAT2 protein. The investigator also proposes to investigate whether there are aberrant EAAT2 mRNAs in transgenic mice with APP (amyloid precursor protein) mutations. Can aberrant EAAT2 mRNAs lead to loss of EAAT2 protein and contribute to neurodegeneration in vivo? To answer this they will generate transgenic mice manifesting astrocyte-specific expression of the human wild-type and aberrant EAAT2 mRNAs. What mechanism accounts for these aberrant splicing defects? They will determine whether there are acquired somatic mutations in the EAAT2 gene. The investigator proposes to develop astrocyte cultures from AD brain and determine if the aberrant EAAT2 mRNAs can be produced in vitro.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH059805-06
Application #
6639106
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Asanuma, Chiiko
Project Start
1999-06-01
Project End
2006-05-31
Budget Start
2003-06-01
Budget End
2006-05-31
Support Year
6
Fiscal Year
2003
Total Cost
$217,339
Indirect Cost
Name
Ohio State University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
071650709
City
Columbus
State
OH
Country
United States
Zip Code
43210
Tian, Guilian; Kong, Qiongman; Lai, Liching et al. (2010) Increased expression of cholesterol 24S-hydroxylase results in disruption of glial glutamate transporter EAAT2 association with lipid rafts: a potential role in Alzheimer's disease. J Neurochem 113:978-89
Chang, Yueming; Stockinger, Michael P; Tashiro, Hirofumi et al. (2008) A novel noncoding RNA rescues mutant SOD1-mediated cell death. FASEB J 22:691-702
Shan, Xiu; Lin, Chien-Liang Glenn (2006) Quantification of oxidized RNAs in Alzheimer's disease. Neurobiol Aging 27:657-62
Guo, Hong; Lai, Liching; Butchbach, Matthew E R et al. (2003) Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum Mol Genet 12:2519-32
Shan, Xiu; Tashiro, Hirofumi; Lin, Chien-liang Glenn (2003) The identification and characterization of oxidized RNAs in Alzheimer's disease. J Neurosci 23:4913-21
Guo, Hong; Lai, Liching; Butchbach, Matthew E R et al. (2002) Human glioma cells and undifferentiated primary astrocytes that express aberrant EAAT2 mRNA inhibit normal EAAT2 protein expression and prevent cell death. Mol Cell Neurosci 21:546-60